20.12.2016 • NewscancerCollaborationSmall Molecules

Proteros Signs Second Oncology Collaboration with MSD

Proteros Biostructures has entered into a second research agreement with Merck Sharp & Dohme (known as MSD outside the US and Canada). The new collaboration is aimed at developing small molecule compounds against an additional epigenetic target for the potential treatment of various cancers.

Under the terms of the agreement, Proteros will receive an upfront payment and research funding and will be eligible to receive development, regulatory and commercial milestone payments up to $167 million plus tiered royalties. Additional details of the collaboration were not disclosed.

Dr. Torsten Neuefeind, CEO of Proteros commented: “We are pleased to expand our relationship with MSD just one year after starting our first collaboration in epigenetic drug discovery. This new collaboration will benefit from our previous and ongoing work with the team at MSD and we look forward to a further successful partnership, which potentially could transform the treatment of many cancers.”

Company

Logo:

Merck & Co

126 East Lincoln Avenue
07065 Rahway
US

Company contact







Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.